Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations (2024) Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, et al. Journal article High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma (2024) Klümper N, Cox A, Eckstein M, Kuppe C, Ritter M, Brossart P, Luetkens J, et al. Journal article Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis (2024) Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, Barrios C, et al. Journal article Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors (2024) Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, et al. Journal article Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB (2024) Amaral T, Nanz L, Stadler R, Berking C, Ulmer A, Forschner A, Meiwes A, et al. Journal article The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects (2024) Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon Mv, Subklewe M, et al. Journal article Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer (2024) Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, et al. Journal article Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. (2024) Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, et al. Journal article Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp (2023) Hassel JC, Berking C, Forschner A, Gebhardt C, Heinzerling L, Meier F, Ochsenreither S, et al. Journal article Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study (2023) Lodde GC, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Hauschild A, et al. Journal article